Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Structure and Function of Platelets01:18

Structure and Function of Platelets

The cell fragments known as platelets are disc-shaped, with an average diameter of about 3 μm and a thickness of roughly 1 μm. They play a crucial role in the body's vascular clotting system, which also involves plasma proteins, blood cells, and blood vessel tissues.
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000 platelets, with...
Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis01:25

Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis

Type 2 diabetes mellitus develops gradually and is often asymptomatic in early stages.Clinical ManifestationsWhen symptoms appear, they include fatigue, blurred vision, pruritus, delayed wound healing, and recurrent infections, particularly candidal infections. Peripheral neuropathy may present as numbness or tingling in the extremities. Classic hyperglycemia symptoms—polyuria, polydipsia, and polyphagia—are less common. Most patients are overweight and frequently have associated hypertension...
Formation of the Platelet Plug01:22

Formation of the Platelet Plug

The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
Diabetic Retinopathy01:27

Diabetic Retinopathy

DefinitionDiabetic retinopathy is a microvascular complication of diabetes affecting the retinal blood vessels.Risk FactorsDiabetic retinopathy is present in almost all individuals with type 1 diabetes and more than 60% of those with type 2 diabetes after two decades of disease.The risk increases with poor glycemic control, hypertension, dyslipidemia, smoking, pregnancy, and puberty.Although cataracts and glaucoma are also more frequent in people with diabetes, retinopathy remains the leading...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Hyperglycemia01:29

Hyperglycemia

Hyperglycemia is an abnormally high blood glucose level. It is diagnosed by fasting glucose ≥126 mg/dL, 2-hour oral glucose tolerance test (or OGTT) ≥200 mg/dL, random glucose ≥200 mg/dL with symptoms, or HbA1c ≥6.5%. However, HbA1c results may be unreliable in certain conditions, such as anemia or hemoglobinopathies, and the diagnosis should be confirmed unless classic symptoms are present. Postprandial hyperglycemia is typically considered significant when glucose levels exceed 180 mg/dL two...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Aspirin for Primary Prevention of Cardiovascular Disease in the 21<sup>st</sup> Century: A Review of the Evidence.

The American journal of cardiology·2021
Same author

Impact of renal function in high bleeding risk patients undergoing percutaneous coronary intervention: a patient-level stratified analysis from four post-approval studies.

Journal of thrombosis and thrombolysis·2021
Same author

Effects of D-allulose on glucose tolerance and insulin response to a standard oral sucrose load: results of a prospective, randomized, crossover study.

BMJ open diabetes research & care·2021
Same author

Ticagrelor Monotherapy Versus Dual-Antiplatelet Therapy After PCI: An Individual Patient-Level Meta-Analysis.

JACC. Cardiovascular interventions·2021
Same author

Use of the VerifyNow point of care assay to assess the pharmacodynamic effects of loading and maintenance dose regimens of prasugrel and ticagrelor.

Journal of thrombosis and thrombolysis·2021
Same author

Predictors, Type, and Impact of Bleeding on the Net Clinical Benefit of Long-Term Ticagrelor in Stable Patients With Prior Myocardial Infarction.

Journal of the American Heart Association·2021

Related Experiment Video

Updated: May 14, 2026

Preparation of Washed Human Platelets for Quantitative Metabolic Flux Studies
07:06

Preparation of Washed Human Platelets for Quantitative Metabolic Flux Studies

Published on: January 10, 2025

Platelet function profiles in patients with diabetes mellitus.

Fabiana Rollini1, Francesco Franchi, Ana Muñiz-Lozano

  • 1University of Florida College of Medicine-Jacksonville, 655 West 8th Street, Jacksonville, FL 32209, USA.

Journal of Cardiovascular Translational Research
|February 14, 2013
PubMed
Summary

Patients with diabetes mellitus (DM) exhibit heightened platelet activity, increasing their risk for cardiovascular events. Current antiplatelet therapies are often insufficient, necessitating novel treatment strategies to mitigate this atherothrombotic risk.

More Related Videos

Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

Dynamic Multiparameter Platelet Function Assessment Using a Capacitive Biosensor
06:32

Dynamic Multiparameter Platelet Function Assessment Using a Capacitive Biosensor

Published on: May 2, 2025

Related Experiment Videos

Last Updated: May 14, 2026

Preparation of Washed Human Platelets for Quantitative Metabolic Flux Studies
07:06

Preparation of Washed Human Platelets for Quantitative Metabolic Flux Studies

Published on: January 10, 2025

Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

Dynamic Multiparameter Platelet Function Assessment Using a Capacitive Biosensor
06:32

Dynamic Multiparameter Platelet Function Assessment Using a Capacitive Biosensor

Published on: May 2, 2025

Area of Science:

  • Cardiology
  • Hematology
  • Endocrinology

Background:

  • Diabetes mellitus (DM) is a global epidemic strongly linked to increased cardiovascular morbidity and mortality.
  • DM patients face elevated risks for coronary heart disease, stroke, peripheral arterial disease, and heart failure.
  • Platelet hyperreactivity in DM contributes significantly to atherothrombotic events.

Purpose of the Study:

  • To review current knowledge on platelet function in DM patients.
  • To discuss the implications of platelet hyperreactivity for cardiovascular risk.
  • To explore therapeutic considerations for antiplatelet treatment in DM.

Main Methods:

  • Literature review of studies on platelet function in diabetes.
  • Analysis of mechanisms underlying platelet hyperreactivity in DM.
  • Evaluation of current antiplatelet treatment efficacy and limitations in DM.

Main Results:

  • DM is characterized by platelet hyperreactivity, enhancing atherothrombotic risk.
  • A significant number of DM patients show suboptimal responses to standard antiplatelet drugs.
  • This leads to a high incidence of recurrent cardiovascular events despite treatment adherence.

Conclusions:

  • Novel antiplatelet treatment strategies are crucial for managing DM patients.
  • Addressing platelet dysfunction is key to reducing cardiovascular events in this population.
  • Further research into tailored antiplatelet regimens for DM is warranted.